Navigation Links
Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Date:7/30/2008

Clinical Program Leverages Quark's RNAi Technology

FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating

PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME).

PF-4523655 is a novel siRNA drug candidate being co-developed by Quark and Pfizer. As part of the companies' Global Licensing Agreement, the successful commencement of the trial triggers a milestone payment to Quark from Pfizer, a small percentage of which is payable by Quark to Silence Therapeutics and Alnylam as technology license milestone payments.

The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-4523655 versus laser therapy in 160 DME patients at multiple centers worldwide. PF-4523655 was designed to inhibit Quark's proprietary target RTP801, a gene involved in abnormal blood vessel development and leakage in the eye. Under the companies' Global Licensing Agreement, Pfizer has exclusive development rights to siRNA-mediated therapies that inhibit RTP801 for ophthalmic and non-ophthalmic indications, while Quark is eligible for development and sales based milestone payments.

Elena Feinstein, Chief Scientific Officer of Quark, commented, "By targeting the RTP801 gene, PF-4523655 is differentiated from other therapeutics for the same ophthalmic indications. While many competitors target VEGF and its receptors, PF-4523655 inhibits abnormal blood vessel growth and leakage independently of the VEGF pathway, reduces inflammation and suppresses apoptosis. Therefore,

PF-4523655 is a siRNA therapeutic candidate with the potential to be efficacious when used as a monotherapy and in combination with existing VEGF-based therapies."

Shai Erlich, Chief Development
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
8. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... its operating results for the second quarter of fiscal ... company will hold a conference call to discuss its ... parties, at 1:30 p.m., Pacific Daylight Time (4:30 p.m., ...
(Date:7/21/2014)... /PRNewswire-iReach/ -- Top Brooklyn Pediatrician Dr. ... article, which suggests that caffeine may be dangerous, according ... A few decades ago parents ... but now it happens rather frequently, according to an ... in the journal Pediatrics, discussed a new study, which ...
(Date:7/21/2014)... 2014 UBM Medica US announces that ... community for primary care clinicians offers a photo collection ... victims of a variety of summer scourges.  ... a host of medical menaces: poison ivy, tick-borne infections, ... the highlights covered on Consultantlive,s topic center that includes ...
Breaking Medicine Technology:Thoratec Schedules Second Quarter Conference Call, Webcast 2Dr. Michael Gabriel a Brooklyn Pediatrician Comments on an Article, Which Suggests Caffeine May Be Dangerous for Children 2ConsultantLive Presents Special Coverage of Summer Scourges 2ConsultantLive Presents Special Coverage of Summer Scourges 3
... 2007 - An alarming study,that appeared in the ... of the American Cancer Society), reports that one-third ... hormonal breast,cancer treatment tamoxifen citrate, discontinue therapy early.(1), ... a major issue that may negatively affect treatment ...
... 2007 - ArQule, Inc.,(NASDAQ: ARQL) today announced that ... for oral presentation the,Company's abstract for ARQ 197 ... a Selective Inhibitor of the c-Met Receptor in ... Annual Meeting, June,1-5, 2007, in Chicago. This presentation ...
Cached Medicine Technology:One-Third of Patients Discontinue Common Breast Cancer Therapy 2One-Third of Patients Discontinue Common Breast Cancer Therapy 3ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 2ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 3ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 4
(Date:7/22/2014)... Pompano Beach, Florida (PRWEB) July 22, 2014 ... and alcohol treatment center located in Pompano ... of approval from the Joint Commission, an independent ... the United States. Accreditation signifies that the quality ... the Joint Commission standards for safety and performance. ...
(Date:7/22/2014)... Coral, FL (PRWEB) July 22, 2014 ... has opened registration for multiple upcoming real estate investing ... These potentially life-changing events are designed to introduce people ... using in the Canadian market. , A total of ... over a period of three weeks. The goal is ...
(Date:7/22/2014)... 22, 2014 2014 ST. JOHN’S, CONSUMER ... to announce the 2014 Top Service Providers in their ... extend heartfelt congratulations to all this year’s winners; your ... of St. John’s. , Each year across Canada, Consumer ... responses of thousands of consumers and businesses. All winners ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Recently, 2014quinceaneradresses.com, ... has announced its latest assortment of blue and ... promotional prices on these special Quinceanera gowns, hoping to ... before July 30 can get a discounted price, up ... very glad to announce these new items. As one ...
(Date:7/22/2014)... Carolina (PRWEB) July 22, 2014 One woman ... solution managed to lose 20 pounds. Unfortunately, the weight loss ... nauseated for the duration of her time using the pill, ... woman experienced heart flutters and insomnia as a result of ... a heart attack at the age of 37 because of ...
Breaking Medicine News(10 mins):Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3Health News:Brick Buy Brick Announces Multiple 1-Day Real Estate Workshops Coming to Toronto 2Health News:2014 St. John's Consumer Choice Award Winners 2Health News:2014 St. John's Consumer Choice Award Winners 3Health News:2014 St. John's Consumer Choice Award Winners 4Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2
... the best way to fix the broken health care system is a ... from an employment based insurance system. , ... Brookfield, Wisconsin (PRWEB) November ... to fix the broken health care system is a complete overhaul, they ...
... two radio frequency modes into one device. The Accent Dual Mode RF ... on both shallow and deep tissue depths. The technology is the latest ... and Laser Center. , ... New York, NY (PRWEB) November 13, 2008 ...
... 13 TheraQuest Biosciences, Inc. a,development stage ... U.S.,Food and Drug Administration (FDA) has accepted ... its abuse deterrent extended release,strong opioid. TQ-1015 ... deterrent technology., Najib Babul, PharmD, Chief ...
... of members, SEIU officials shut down,California offices ahead ... Caregivers who work in,California hospitals, nursing homes, and ... offices of their national union, the Service,Employees International ... United Healthcare Workers-West (UHW), a,local union that has ...
... helps prevent malaria, ALEPE, Cote d,Ivoire, Nov. ... and their partners worldwide helped Cote d,Ivoire,s,National Program ... health,campaign November 11 that will vaccinate 3.5 million ... the country with bed nets to,stop the spread ...
... 12 Amilpar,(BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: AMIL3.SA), ... for the third quarter of 2008., 3rd Quarter ... at the end of September, up 18.2% ... than the previous quarter. -- Adjusted Operating Revenues totaled ...
Cached Medicine News:Health News:Employers Want National Approach to Health Care—Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 2Health News:Employers Want National Approach to Health Care—Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 3Health News:Accent Dual Mode Skin Tightening Laser is Latest Offering from Juva Skin Center 2Health News:TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA 2Health News:Healthcare Workers Picket Their National Union to Protect Their Voice for Patients 2Health News:Photo: United Methodist Church, Partners Launch Life-Saving Campaign in Cote d'Ivoire 2Health News:Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: